Epigenetic therapy shows promise against treatment-resistant AML. Researchers at The University of Texas MD Anderson Cancer Center have discovered that an investigational epigenetic therapy remained effective in treatment-resistant acute myeloid leukemia (AML) by activating the Hippo pathway, a tumor-suppressing pathway linked to cancer growth and drug resistance.
A apuração publicada por medicalxpress.com vira base para uma leitura editorial direta e contextualizada.
Trechos de apoio da pauta: Researchers at The University of Texas MD Anderson Cancer Center have discovered that an investigational epigenetic therapy remained effective in treatment-resistant acute myeloid leukemia (AML) by activating the Hippo pathway, a tumor-suppressing pathway linked to cancer growth and drug resistance.
- Ponto de atenção: epigenetic.
- Ponto de atenção: therapy.
- Ponto de atenção: shows.
Em resumo, a leitura editorial acompanha o impacto do tema no nicho Fitness.
:quality(85)/714bb402-38e3-43bf-8898-7556dcd88307.jpeg)
:quality(85)/b2559bc4-a3f9-4524-8599-e1e7c27867ef.png)